RespireRx Pharmaceuticals Inc. Announces New Research Program with the National Institute of Drug Abuse
RespireRx Expands Research Initiatives Involving Treatments for Drugs of Abuse Glen Rock, N.J., January 19, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) announces that the Company has reached an agreement with the Medications Development Program of the National Institute of Drug Abuse (“NIDA”) for NIDA to conduct research on RespireRx…